Obefazimod is under clinical development by Abivax and currently in Phase II for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase II drugs for Crohn’s Disease (Regional Enteritis) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Obefazimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABX-464 is under development for the treatment of Crohn's disease, HIV infection, multiple sclerosis, Parkinson's disease, psoriasis, rheumatoid arthritis, ulcerative colitis, non-alcoholic steatohepatitis (NASH) and pulmonary arterial hypertension. The drug candidate is first in class small molecule administered through the oral route as a capsule. The drug candidate acts by targeting Rev activity by blocking the cap-binding complex (CBC) on mRNA. It also acts by upregulating IL-22 and miR124. The drug candidate is based on Antiviral platform.
It was under development for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients.
Abivax operates as a biotechnology company. It develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company offers pipeline products that include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora. Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus infection. The company also develops various technology platforms including antiviral platform, immune enhancer platform and polyclonal antibody platform. Abivax is headquartered in Paris, France.
For a complete picture of Obefazimod’s drug-specific PTSR and LoA scores, buy the report here.